Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delivering a New Future for People With Cystic Fibrosis.

Pediatrics - 1 Oct 2023

Burgener Elizabeth B, Cornfield David N

Abstract excerpt

Treatment, prognosis, and quality of life for people with cystic fibrosis (CF) have improved steadily since the initial description of the disease, but most dramatically in the past decade. In 2021, the median predicted survival increased to 53 years, compared with 17 years in 1970. The recent improvement in outcomes is attributable to the advent of cystic fibrosis transmembrane regulator (CFTR) modulators, small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Quality of Life

Source

Open in PubMed Open full text

Identifiers

PMID: 37671451
DOI: 10.1542/peds.2023-062985
PMCID: PMC10522926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delivering a New Future for People With Cystic Fibrosis.PMID 37671451Read ↗

A new era for people with cystic fibrosis.Semantic proximity Read ↗

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.Semantic proximity Read ↗

Considerations for early life genetic therapies in cystic fibrosis.Semantic proximity Read ↗

The New and Advanced Cystic fibrosis transmembrane conductance regulators Modulators in Children with Cystic Fibrosis: A Narrative Review on Long-Term Outcomes, Recent Advances, and Comparative Insights.Semantic proximity Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

Precision Medicine Based on CFTR Genotype for People with Cystic FibrosisSemantic proximity Read ↗

Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity Read ↗

Cystic fibrosis year in review 2021.Semantic proximity Read ↗

Future therapies for cystic fibrosis.Semantic proximity Read ↗

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?Semantic proximity Read ↗

Advances in the diagnosis and treatment of cystic fibrosis.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.